Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00348192 |
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.
Condition | Intervention | Phase |
---|---|---|
Alzheimer's Disease |
Drug: SB-742457 Drug: donepezil |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease |
Estimated Enrollment: | 200 |
Study Start Date: | May 2006 |
Ages Eligible for Study: | 50 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Austria | |
GSK Investigational Site | |
Hall in Tirol, Austria, A-6060 | |
GSK Investigational Site | |
Vienna, Austria, A-1130 | |
GSK Investigational Site | |
Vienna, Austria, A-1220 | |
Bulgaria | |
GSK Investigational Site | |
Varna, Bulgaria, 9010 | |
GSK Investigational Site | |
Sofia, Bulgaria, 1431 | |
GSK Investigational Site | |
Sofia, Bulgaria, 1113 | |
Chile, Región Metro De Santiago | |
GSK Investigational Site | |
Santiago, Región Metro De Santiago, Chile, 7560356 | |
GSK Investigational Site | |
Providencia / Santiago, Región Metro De Santiago, Chile, 7500710 | |
Chile, Valparaíso | |
GSK Investigational Site | |
Valparaiso, Valparaíso, Chile, 2352499 | |
Estonia | |
GSK Investigational Site | |
Tartu, Estonia, 51014 | |
GSK Investigational Site | |
Tallinn, Estonia, 10617 | |
Germany, Baden-Wuerttemberg | |
GSK Investigational Site | |
Ostfildern, Baden-Wuerttemberg, Germany, 73760 | |
Germany, Hessen | |
GSK Investigational Site | |
Huettenberg, Hessen, Germany, 35625 | |
Germany, Niedersachsen | |
GSK Investigational Site | |
Achim, Niedersachsen, Germany, 28832 | |
Germany, Nordrhein-Westfalen | |
GSK Investigational Site | |
Baesweiler, Nordrhein-Westfalen, Germany, 52499 | |
GSK Investigational Site | |
Hattingen, Nordrhein-Westfalen, Germany, 45525 | |
Russian Federation | |
GSK Investigational Site | |
Moscow, Russian Federation, 115552 | |
GSK Investigational Site | |
St. Petersburg, Russian Federation, 197022 | |
GSK Investigational Site | |
St.-Petersburg, Russian Federation, 198103 | |
GSK Investigational Site | |
Moscow, Russian Federation, 117049 | |
Slovakia | |
GSK Investigational Site | |
Bratislava, Slovakia, 831 03 | |
GSK Investigational Site | |
Bratislava, Slovakia, 826 06 | |
GSK Investigational Site | |
Bratislava, Slovakia, 811 01 | |
United Kingdom | |
GSK Investigational Site | |
West of Scotland Science Park, Glasgow, United Kingdom, G20 0XA | |
GSK Investigational Site | |
Bradford, United Kingdom, BD7 1HR | |
GSK Investigational Site | |
Swindon, United Kingdom, SN1 4HZ |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | AZ3106242 |
Study First Received: | June 30, 2006 |
Last Updated: | May 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00348192 History of Changes |
Health Authority: | Austria: Federal Ministry for Health and Women |
Alzheimer's Disease cognition global functioning symptomatic SB-742457 |
Nootropic Agents Neurotransmitter Agents Alzheimer Disease Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Cholinergic Agents |
Cognition Disorders Cholinesterase Inhibitors Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Donepezil Dementia Delirium |
Nootropic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Alzheimer Disease Nervous System Diseases Central Nervous System Diseases Enzyme Inhibitors Cholinergic Agents Brain Diseases |
Neurodegenerative Diseases Pharmacologic Actions Cholinesterase Inhibitors Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Therapeutic Uses Donepezil Dementia Tauopathies Central Nervous System Agents |